Wells Fargo raised the firm’s price target on Eli Lilly to $825 from $700 and keeps an Overweight rating on the shares. After a solid 2024 guidance and encouraging early data in NASH, the firm feels “incrementally confident” about Eli Lilly’s Buy thesis and now sees peak GLP/GIP opportunity at $140B, versus previous $115B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Gains after Strong Q4 Results
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
- Notable companies reporting before tomorrow’s open
- Eli Lilly Stock: All Eyes on Earnings This Week — Here’s What J.P. Morgan Expects